Peripheral Arterial Disease (PAD) Market Is Poised To Expand at a Robust Pace By 2027 | Bayer AG, Abbott, Boston Scientific Corporation, BIOTRONIK - Owned
Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Comments
Post a Comment